Lifeway Foods Reports Record-Breaking Full Year 2025 Results: Sixth Consecutive Year of Growth and Robust Outlook for 2026

Key Highlights

• Full Year 2025 Net Sales: \$212.5 million (up 13.7% YoY; 19% on a comparable basis)
• Fourth Quarter 2025 Net Sales: \$55.4 million (up 18.0% YoY)
• Gross Margin Expansion: Annual gross margin up 140 basis points to 27.4% (Q4 margin: 27.8%, up 250 basis points)
• Net Income: \$13.9 million for 2025 (up 54% YoY); Q4 net income \$2.5 million vs. prior year Q4 net loss of \$0.2 million
• Strategic Innovations: New product launches including Muscle Mates™, Lifeway Kefir Butter™, and expanded Farmer Cheese line
• Positive Industry Validation: U.S. government dietary guidelines now specifically highlight kefir and fermented foods
• Strong Guidance: Company reiterates FY 2027 Adjusted EBITDA target of \$45–\$50 million

Detailed Financial Performance

Lifeway Foods, Inc. (Nasdaq: LWAY), the leading U.S. supplier of kefir and fermented probiotic foods, delivered exceptional results for the fourth quarter and full year ended December 31, 2025. Net sales for the year reached an all-time high of \$212.5 million, marking a 13.7% increase year-over-year and an impressive 19% rise on a comparable basis, after adjusting for the strategic exit of a customer relationship and changes in distributor arrangements in 2024. This milestone cements Lifeway’s sixth consecutive year of volume-led sales growth.

The fourth quarter capped off the year with net sales of \$55.4 million, reflecting 18% growth over the prior year period. Gross profit margin expanded by a robust 250 basis points in Q4, reaching 27.8%, while the full-year margin improved 140 basis points to 27.4%. This margin expansion underscores the company’s disciplined operational execution and the scalability of its business model.

Selling, general, and administrative expenses rose slightly to \$11.5 million in Q4, driven by continued investments in marketing and brand awareness. Full-year SG&A as a percentage of net sales was 19.6%, up marginally from the prior year, reflecting the company’s focused brand-building efforts.

The year ended with net income of \$13.9 million, or \$0.91 per basic share (\$0.89 diluted), a significant increase from \$9.0 million, or \$0.61 per basic share (\$0.60 diluted) the previous year. In Q4, net income was \$2.5 million (\$0.17 per basic share, \$0.16 diluted), compared to a net loss in Q4 2024.

Strategic and Operational Drivers

• Marketing Momentum: The company’s marketing investments are translating into top-line growth, as consumers embrace flagship products like Lifeway Kefir and high-protein Farmer Cheese. New social campaigns and partnerships with sports personalities (e.g., Colston Loveland and D’Andre Swift) and fitness brands (Barry’s Fuel Bar) are raising national awareness and expanding market reach.
• Innovation Pipeline: Lifeway is capitalizing on consumer trends with the introduction of Muscle Mates™ and Lifeway Kefir Butter™, available in Unsalted, Sea Salt, and Honey Butter varieties. The company’s expertise in cultured dairy positions it well to exploit renewed momentum in the butter category.
• Dietary Guidelines Validation: Recent U.S. government dietary guidelines specifically mention kefir and fermented foods, highlighting their importance for gut health. Lifeway’s alignment with these guidelines gives it a competitive advantage as consumer focus intensifies on protein-rich, probiotic, and bioavailable foods.
• GLP-1 Medication Tailwinds: As awareness of GLP-1 medications grows, Lifeway’s nutrient-dense, gut-friendly offerings are well-positioned to serve both active medication users and health-conscious consumers seeking natural solutions that stimulate GLP-1 hormone production.

Balance Sheet & Cash Flow

• Cash and Equivalents (End 2025): \$5.6 million (vs. \$16.7 million end 2024), reflecting significant investments in property, plant, and equipment (\$27.4 million in 2025 vs. \$6.7 million in 2024).
• Total Assets: \$105.6 million (up from \$90.5 million in 2024).
• Stockholders’ Equity: \$85.8 million (up from \$71.9 million in 2024).
• Net Cash from Operations: \$10.9 million (down from \$13.0 million in 2024), reflecting higher inventory and accounts receivable tied to growth and capital investments.

Forward Guidance and Outlook

Lifeway reaffirmed its long-term Adjusted EBITDA target of \$45–\$50 million for fiscal year 2027 and expects 2026 to be another record sales year. Management emphasized ongoing investments in capacity, marketing, and innovation as foundational to durable, long-term value creation. The company believes it is exceptionally well-positioned to capitalize on the significant opportunities ahead in the health and wellness market.

Risks and Considerations

• The company notes that its forward-looking statements are subject to risks including price competition, changes in customer or consumer behavior, commodity pricing, regulatory impacts, and the success of new product launches.
• Lifeway’s significant capital expenditures in 2025 may impact short-term liquidity but are intended to drive future capacity and growth.

Price-Sensitive and Shareholder-Relevant Items

• Record-breaking sales and margin expansion, alongside a 54% increase in net income, are highly positive and may be viewed as share price supportive.
• Major investments in capacity and innovation signal management’s confidence in continued growth.
• Positive industry and regulatory validation of Lifeway’s core products could drive further upside.
• 2026 guidance and reiterated long-term EBITDA targets provide visibility and may reduce perceived risk for investors.

Conclusion

Lifeway Foods delivered an exceptional 2025, achieving record sales, expanding margins, and posting robust earnings growth, while laying the groundwork for continued outperformance through strategic investments and innovation. The company’s favorable positioning in the rapidly growing market for probiotic, protein-rich, and gut-health-focused foods—now explicitly recognized in U.S. dietary guidelines—adds further impetus to its growth story.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all relevant filings and conduct their own due diligence before making investment decisions. Forward-looking statements are subject to risks and uncertainties as outlined in Lifeway’s official disclosures.

View Lifeway Foods, Inc. Historical chart here